Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome

Tomonori Wada, Yuji Yoshikawa, Naohisa Yahagi, Norio Kawamura, Nobuyuki Kakei, Yasuo Matsubara, Masahiro Tsuji, Kazumasa Miki

Research output: Contribution to journalArticle

Abstract

The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR237 G : 3.0g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as moderately improved or more were 59.1% (13/22) and 68.2%(15/22), respectively. The rates in the final global improvement was 68.2%(15/22). The rates in the diarrhea and constipation predominant cases were 66.7%(12/18) and 75.0%(3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0%(I/ 25), which was slightly and not serious. The rate of the cases assessed asno problem in safety in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as useful or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.

Original languageEnglish
Pages (from-to)231-232
Number of pages2
JournalFortschritte der Medizin
Volume116
Issue number32
Publication statusPublished - 1998 Nov 20
Externally publishedYes

Fingerprint

Irritable Bowel Syndrome
Safety
Constipation
Diarrhea
calcium polycarbophil
Clinical Studies

Keywords

  • Calcium polycarbophil
  • Constipation
  • Diarrhea
  • Fine granule
  • Gastrointestinal symptoms
  • Irritable bowel syndrome
  • Stool disorders

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wada, T., Yoshikawa, Y., Yahagi, N., Kawamura, N., Kakei, N., Matsubara, Y., ... Miki, K. (1998). Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. Fortschritte der Medizin, 116(32), 231-232.

Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. / Wada, Tomonori; Yoshikawa, Yuji; Yahagi, Naohisa; Kawamura, Norio; Kakei, Nobuyuki; Matsubara, Yasuo; Tsuji, Masahiro; Miki, Kazumasa.

In: Fortschritte der Medizin, Vol. 116, No. 32, 20.11.1998, p. 231-232.

Research output: Contribution to journalArticle

Wada, T, Yoshikawa, Y, Yahagi, N, Kawamura, N, Kakei, N, Matsubara, Y, Tsuji, M & Miki, K 1998, 'Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome', Fortschritte der Medizin, vol. 116, no. 32, pp. 231-232.
Wada T, Yoshikawa Y, Yahagi N, Kawamura N, Kakei N, Matsubara Y et al. Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. Fortschritte der Medizin. 1998 Nov 20;116(32):231-232.
Wada, Tomonori ; Yoshikawa, Yuji ; Yahagi, Naohisa ; Kawamura, Norio ; Kakei, Nobuyuki ; Matsubara, Yasuo ; Tsuji, Masahiro ; Miki, Kazumasa. / Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. In: Fortschritte der Medizin. 1998 ; Vol. 116, No. 32. pp. 231-232.
@article{7446e1e34d2347b387628c36b4523e5a,
title = "Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome",
abstract = "The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR237 G : 3.0g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as moderately improved or more were 59.1{\%} (13/22) and 68.2{\%}(15/22), respectively. The rates in the final global improvement was 68.2{\%}(15/22). The rates in the diarrhea and constipation predominant cases were 66.7{\%}(12/18) and 75.0{\%}(3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0{\%}(I/ 25), which was slightly and not serious. The rate of the cases assessed asno problem in safety in the overall safety rating was 96.0{\%} (24/25). In the global utility rating, the rate of cases assessed as useful or more was 63.6{\%} (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.",
keywords = "Calcium polycarbophil, Constipation, Diarrhea, Fine granule, Gastrointestinal symptoms, Irritable bowel syndrome, Stool disorders",
author = "Tomonori Wada and Yuji Yoshikawa and Naohisa Yahagi and Norio Kawamura and Nobuyuki Kakei and Yasuo Matsubara and Masahiro Tsuji and Kazumasa Miki",
year = "1998",
month = "11",
day = "20",
language = "English",
volume = "116",
pages = "231--232",
journal = "Fortschritte der Medizin",
issn = "0015-8178",
publisher = "Urban und Vogel",
number = "32",

}

TY - JOUR

T1 - Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome

AU - Wada, Tomonori

AU - Yoshikawa, Yuji

AU - Yahagi, Naohisa

AU - Kawamura, Norio

AU - Kakei, Nobuyuki

AU - Matsubara, Yasuo

AU - Tsuji, Masahiro

AU - Miki, Kazumasa

PY - 1998/11/20

Y1 - 1998/11/20

N2 - The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR237 G : 3.0g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as moderately improved or more were 59.1% (13/22) and 68.2%(15/22), respectively. The rates in the final global improvement was 68.2%(15/22). The rates in the diarrhea and constipation predominant cases were 66.7%(12/18) and 75.0%(3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0%(I/ 25), which was slightly and not serious. The rate of the cases assessed asno problem in safety in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as useful or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.

AB - The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR237 G : 3.0g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as moderately improved or more were 59.1% (13/22) and 68.2%(15/22), respectively. The rates in the final global improvement was 68.2%(15/22). The rates in the diarrhea and constipation predominant cases were 66.7%(12/18) and 75.0%(3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0%(I/ 25), which was slightly and not serious. The rate of the cases assessed asno problem in safety in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as useful or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.

KW - Calcium polycarbophil

KW - Constipation

KW - Diarrhea

KW - Fine granule

KW - Gastrointestinal symptoms

KW - Irritable bowel syndrome

KW - Stool disorders

UR - http://www.scopus.com/inward/record.url?scp=34249985079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249985079&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34249985079

VL - 116

SP - 231

EP - 232

JO - Fortschritte der Medizin

JF - Fortschritte der Medizin

SN - 0015-8178

IS - 32

ER -